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Preimplantation genetic diagnosis is a procedure that involves the removal of one or more nuclei from
oocytes (a polar body) or embryos (blastomeres or trophectoderm cells) in order to test for problems in
genome sequence or chromosomes of the embryo prior to implantation. It provides new hope of having
unaffected children, as well as avoiding the necessity of terminating an affected pregnancy for genetic
parents who carry an affected gene or have balanced chromosomal status. Polymerase chain reaction-
based molecular techniques are the methods used to detect gene defects with a known sequence and
X-linked diseases. The indication for using this approach has expanded for couples who are prevented
from having babies because they carry a serious genetic disorder to couples with conditions that are not
immediately life threatening, such as cancer predisposition genes and Huntington disease. In addition,
ﬂuorescent in situ hybridization (FISH) has been widely applied for the detection of chromosome ab-
normalities. FISH allows the evaluation of many chromosomes at the same time, up to 15 chromosome
pairs in a single cell. Preimplantation genetic screening, deﬁned as a test that screens for aneuploidy, has
been most commonly used in situations of advanced maternal age, a history of recurrent miscarriage, a
history of repeated implantation failure, or a severe male factor. Unfortunately, randomized controlled
trials have as yet shown no beneﬁt with respect to preimplantation genetic screening using cleavage
stage biopsy, which is probably attributable to the high levels of mosaicism at early cleavage stages and
the limitations of FISH. Recently, two main types of array-based technology combined with whole
genome ampliﬁcation have been developed for use in preimplantation genetic diagnosis; these are
comparative genomic hybridization and single nucleotide polymorphism-based arrays. Both allow the
analysis of all chromosomes, and the latter also allows the haplotype of the sample to be determined. The
promising results of these two approaches will inspire further validation of these array platforms, even at
the single-cell level. It remains to be decided which embryo stage is the best for biopsy. Moreover, if
randomized controlled trials are conﬁrmed to play a role in increasing delivery rates, this will be a major
step forward for assisted reproductive technology patients around the world.
Copyright  2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Preimplantation genetic diagnosis (PGD) is a procedure that
involves the removal prior to the implantation of one or more
nuclei from oocytes [a polar body or bodies (PBs)] or embryos
(blastomeres or trophectoderm cells) to test for mutations in the
genome sequence or for chromosomal aneuploidy. In 1990, Han-
dyside et al [1] ﬁrst applied PGD to the detection of X chromosome-nd Gynecology, Chang-Gung
oyuan 333, Taiwan.
e).
bstetrics & Gynecology. Publishedlinked diseases in order to achieve successful pregnancies. PGD
techniques are widely carried out bymany in vitro fertilization (IVF)
centers and provide patients with new hope of having unaffected
children, as well as avoiding the necessity of terminating an
affected pregnancy for couples carrying affected genes or chro-
mosome problems.
Preimplantation genetic screening (PGS) is deﬁned as a test
screening for aneuploidy by means of PGD in speciﬁc groups of
patients. Both genetic parents have no known genetic or chromo-
somal problem. The ﬁrst pregnancies using this approach were
reported by Verlinsky et al [2], and these were obtained using
embryos following aneuploidy screening using a ﬂuorescent in situ
hybridization (FISH) probe for chromosomes X, Y, 18, and/or 13/21.by Elsevier Taiwan LLC. All rights reserved.
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means that there is an increased risk of implantation failure and
miscarriage. It is well known that maternal age signiﬁcantly affects
the incidence of aneuploidy in clinically recognized pregnancies; it
dramatically increases from 2% to 3% in the 20- to 25-year group to
35% among women older than 40 years [3,4]. Therefore, PGS has
been most commonly used in women of advanced age. In addition,
PGS is also applied when women have a history of recurrent
miscarriage, when women have a history of repeated implantation
failure (RIF), and when women have a partner with severe male
factor, because of the higher percentage of aneuploidy in embryos
from these groups [5e13]. However, the efﬁcacy of PGS in clinical
practice remains under debate.
This review explores the technology and clinical application of
PGD and the effect of PGS on the probability of live birth after IVF.Biopsy procedure
PGD is a procedure that requires the removal of one or more
cells from embryos in order to have sufﬁcient genetic material for
diagnosis (Table 1). Biopsies are performed using a range of
different methods including PB biopsy from an oocyte or zygote,
cleavage stage biopsy, and blastocyst biopsy. Cleavage stage biopsy
is the most common type of biopsy worldwide, and it has been
reported that 90% of PGD is performed by removal of one or more
blastomeres at cleavage stage [14].
The ﬁrst PB extruded from the oocyte prior to fertilization and
the second PB extruded after fertilization are both not necessary for
subsequent embryo development [15]. Therefore, the ﬁrst or sec-
ond PB can be biopsied without damaging embryo development.
However, it has been shown that approximately 50% of oocytes
with single chromatid errors in the ﬁrst PB undergo normal em-
bryonic development [16]. Postzygotic aneuploidy during
embryogenesis cannot be detected by PB biopsy [17]. Hence, PB
biopsy is limited to only maternal aneuploidies. Nevertheless,
approximately 90% of human aneuploidy originated during
maternal meiosis [18]. Because of this, the European Society for
Human Reproduction and Embryology (ESHRE) PGS task force
hopes to use PB biopsy to detect all chromosomes using molecular
techniques [microarray comparative genomic hybridization (CGH),
multiplex ligation-dependent probe ampliﬁcation (MLPA), etc.]
[19].Table 1
Differences between the biopsy methods used for preimplantation genetic
diagnosis.
Stage of biopsy Advantages Disadvantages and
limitations
Oocyte/zygote
(polar body)
No effect on subsequent
embryo development
Enough time to perform
analysis prior to transfer
Only one or two cells
available for analysis
Only maternal message
obtained DNA liable to
degenerate
Cleavage stage Diagnosis of maternal and
paternal inherited disease
Possibility of sex determination
Up to two cells available for
analysis
Limited time for analysis
High incidence of
chromosomal mosaicism
Blastocyst Fewer number of embryos to
be biopsied and fewer
specimens to process
Three or more cells per embryo
available to overcome allele
dropout
Less problem of mosaicism
Occasions when embryos
failing to blastocysts
Need for cryopreservation
most of the timeCleavage stage biopsy involves one or two cells being biopsied
from embryos if six or more blastomeres are present. The time of
biopsy is on the morning of Day 3 (68e72 hours) after insemina-
tion. Magli et al [20] recommended that very poor quality embryos
are not suitable for PGD. The issue exists as to whether one or two
blastomeres should be removed during cleavage stage biopsy. Hu-
man embryo biopsy for PGD should be envisaged as a balance be-
tween cell retrieval in order to allow a safe and correct diagnosis of
the embryo on the one hand, and safeguarding the implantation
potential of the biopsied embryo on the other. Removing one
blastomere is less invasive than removing two blastomeres and
results in greater numbers of top-quality blastocysts, good-quality
blastocysts, and early blastocysts on Day 5 [21,22]. Nevertheless,
some tests may require the biopsies of two cells to achieve an
acceptable level of diagnostic accuracy.
In recent years, blastocyst biopsy has been increasingly used,
especially over the past 5 years. The human blastocyst consists of an
outer layer of trophectoderm cells and an inner cluster of cells, the
inner cell mass. The procedures for blastocyst biopsy include zona
opening on D3 or on D5 together with removal of trophectoderms.
The ﬁrst human blastocyst biopsywas performed in 1990 by Dokras
and colleagues [23]. The advantages of blastocyst biopsy are that it
can provide more than three blastomeres for analysis and can
overcome the problems of allele dropout (ADO) and ampliﬁcation
failure that are encountered during single cell polymerase chain
reaction (PCR) and FISH. The availability of more cells ought to
increase diagnostic accuracy. Chen et al [24] suggested that blas-
tocyst biopsy provides the advantages of being relatively cost-
effective and being less labor-intensive compared with cleavage
stage biopsy. However, the application of blastocyst biopsy depends
on embryo development, and only 50e60% of embryos are able to
reach blastocyst stage.
A recent systemic review by van Echten-Arends et al [25]
showed that the rate of chromosomal mosaicism of cleavage em-
bryos appears to be as high as 72%. Even at the blastocyst stage,
Fragouli et al [26] demonstrated that 32.4% of blastocysts are
mosaic. Mosaic diploideaneuploid blastocysts with >30% normal
cells account for <6% of the analyzed embryos. Although meiotic
and postzygotic errors leading to mosaicism are common, most
mosaic blastocysts contain no normal cells. They concluded that a-
CGH (array CGH) trophectoderm analysis is an accurate aneuploidy
detection tool that can assist in the identiﬁcation of viable euploid
embryos with a higher implantation potential.
Methods of genetic diagnosis
FISH uses DNA probes labeled with distinctly colored ﬂuoro-
chromes that can bind to speciﬁc DNA sequences on chromosomes.
FISH is used to detect chromosome status, which includes X-linked
diseases, aneuploidy screening, and other structural rearrange-
ments. Over the past decade, FISH has been widely applied for the
detection of chromosome abnormalities [26e31]. FISH allows the
evaluation of many chromosomes at the same time, speciﬁcally up
to 15 chromosome pairs using a single cell [32]. However, the
application of FISH for PGD has several technical limitations
including hybridization failure (lack of FISH signal), signal overlap,
signal splitting, and poor probe hybridization, as well as problems
associated with cell loss and variable cell ﬁxation [33e36]. Some
have reported that the error rate for FISH detection of chromosomal
translocation accounts is in the range of 6% [33,34,37].
Different PCR-related methods, such as ampliﬁcation refractory
mutation system, restriction endonuclease digestion, heteroduplex
analysis, single-strand conformational polymorphism analysis,
denaturant gradient gel electrophoresis, ﬂuorescent PCR, and
multiplex PCR, have been developed to provide the ability to detect
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relation to X-linked disease [38]. Usually, a speciﬁc protocol is
required to carry out PGD when detecting a known genetic disease
[39]. Table 2 summarizes the most common indications for single-
gene defects based on the data collected by the ESHRE PGD Con-
sortium [40]. In Taiwan, the most common indications for single-
gene disorders are a-thalassaemia and b-thalassaemia [41]. The
indication for PGD has developed from the original driving force,
which was couples who were at risk of having a baby carrying a
serious genetic disorder to the conditions that are not immediately
life threatening, such as cancer predisposition genes and Hun-
tington disease. In the latter situation, the couples consider the
genetic predisposition as serious enough to undergo IVF treatment
with PGD in order to avoid the birth of affected childrenwhowill in
the future probably suffer from the disease. In the ESHRE PGD
Consortium report, it is clearly stated that the accuracy of PCR is as
high as 94.1% [42]. However, the application of PCR techniques
continues to encounter various problems, such as ampliﬁcation
failure, ADO, and contamination leading to misdiagnosis. The
incidence of ampliﬁcation failure can be as high as 10% [43]. The
ESHRE guidelines recommended that the rate of ADO needs to be
controlled and should be as low as 10% [44]. ADO is a phenomenon
whereby only one of the two alleles is successfully ampliﬁed and is
equally likely to affect either of the alleles in a heterozygous cell.
The ADO frequency can be estimated, but it is not possible to pre-
dict which allele will be affected in a given reaction. ADO may be a
problem when examining heterozygous embryos. When the ge-
netic disease is dominant, the ADO of the affected allele will lead to
misdiagnosis. When the genetic disease is recessive, the ADO of the
normal allele will also lead to a misdiagnosis. Both of the above
factors may affect the usefulness of a PCR-based molecular
technique.
CGH is a technique that utilizes molecular genetics and cyto-
genetics [45]. DNA from the test sample and DNA from a normal
control DNA are ampliﬁed respectively using whole genome
ampliﬁcation (WGA). Different WGA approaches have been re-
ported, such as degenerate oligonucleotide primer PCR [46,47] and
primer extension preampliﬁcation (PEP) PCR [48], as well as newer
methods such as iPEP (improved PEP) [49], multiple displacement
ampliﬁcation [50,51], and GenomePlex [52]. So far, there seems to
be no universal WGA. The ampliﬁed DNAs are then differentially
labeled with one of two ﬂuorochromes, for example, red for the test
DNA and green for the control DNA. After labeling, both DNAs are
mixed together in equal proportions and are allowed to competi-
tively hybridize to either the metaphase spreads from a normalTable 2
The list of common indications for single-gene defects based on information from
the ESHRE PGD consortium [40].
Disease
Cystic ﬁbrosis
Myotonic dystrophy
Huntington disease
Beta thalassemia
Fragile X syndrome
Spinal muscular atrophy
Hemophilia A
Duchenne muscular dystrophy/Becker muscular dystrophy
Human leukocyte antigen
Othersa
Note. From “The causes of misdiagnosis and adverse outcomes in PGD” by L. Wilton,
A. Thornhill, J. Traeger-Synodinos, K.D. Sermon, and J.C. Harper, 2009, Hum Reprod,
24, p. 1221e8. The Authors 2009. Reproduced with permission.
a Others: sickle cell anemia, neuroﬁbromatosis type 1, tuberous sclerosis, von
Hippel Lindau, familial adenomatous polyposis, CharcoteMarieeTooth disease type
1, Marfan syndrome, familial amyloidotic polyneuropathy.male control cell line (m-CGH) or onto an array platform containing
small pieces of chromosome (a-CGH). Both m-CGH and a-CGH have
been applied in clinical practice [18, 44,53e56]. However, the time-
consuming nature of m-CGH has hindered the wide application of
this approach to PGS. By contrast, the protocol for a-CGH has been
made user-friendly and the time needed to complete the analysis
has been shortened; as a result, it is being increasingly used in
clinical practice. Traversa et al [57] demonstrated the reliability and
feasibility of the CGH approach for the detection of aneuploidy in
patients with RIF and recurrent miscarriage. Nonetheless, there are
still some inadequacies associated with the CGH approach. These
include the inability to differentiate between balanced trans-
locations and inversions, and the inability to detect some types of
speciﬁc ploidy status, such as polyploidy or monoploidy. Further-
more, the systems cannot detect changes in DNA sequences (point
mutations, intragenic insertions or deletions, triplet repeat
expansion, etc.). Finally, they are unable to ﬁnd gains or losses in
regions of the genome not covered by the array [58].
Single nucleotide polymorphisms (SNPs), which are variations
at a single site in DNA, are themost common type of variation in the
genome. SNP microarray analysis is used to detect polymorphisms
that exist at a frequency greater than 1% within a population. SNPs
not only can be applied for single-gene disorder detection as well as
the detection of aneuploidy, but also can be used for determining
which parental haplotype has been transmitted to the embryos
[59e61]. However, there are several limitations to using SNPs in
clinical practice. These include the fact that the association of copy
number variants with clinical information remains unknown and
that parental DNA is required for linkage analysis. The accuracy of
SNPs has been reported to be also limited by contamination and
ADO. Johnson et al [62] found that for the aneuploidy screening
there was a false detection rate of 2.1% using SNP methods
compared to 1% by traditional metaphase karyotyping. In addition,
Bisignano et al [63] pointed out the poor quality of a considerable
amount of SNP genotype information generated by whole-genome
ampliﬁcation as well as the difﬁculty of predicting haplotypes.
Regardless of the method used for WGA, ADO rates for heterozy-
gous SNPs can be as high as 40e50% [63]. Nevertheless, taking this
into account, Handyside [64] believed that the SNP-based array
approach with optimized protocols and parental support algo-
rithmsmay be particularly suited to certain applications such as the
PGD of single-gene defects and translocation chromosome imbal-
ance combined with comprehensive detection of aneuploidy. In
translocation cases, the normal embryos can be differentiated from
balanced ones.
Issues affecting PGS
To the best of our knowledge, the strategy of aneuploidy
screening using PGS for improving the IVF outcomes remains
controversial. Indications for PGS in clinical practice have included
advanced maternal age (AMA; >36 years), RIF (e.g., 3 embryo
transfers with high-quality embryos or the transfer of10 embryos
in multiple transfers, exact numbers to be determined by each
center), and recurrent miscarriage (3 miscarriages) [65]. When
applying PGS to AMA, the results of a prospective randomized
controlled trial (RCT) showed that PGS in women with AMA
resulted in a signiﬁcantly decreased clinical pregnancy rate
compared to those without PGS (8.9% vs. 24.5%) [66]. By contrast, a
retrospective study by Milán et al [67] has suggested that PGS can
improve reproductive success in patients older than 40 years, with
a more than 2-fold increase in ongoing pregnancy rate compared to
non-PGS patients. When using PGS for RIF, one RCT study of nearly
200 patients [68] reported that PGS did not increase the implan-
tation rate and pregnancy rate after IVF intracytoplasmic sperm
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control that assesses the efﬁcacy of PGS on patients with recurrent
miscarriage, although some retrospective studies appear to indicate
that there is a positive effect on patients with recurrent miscarriage
[68e70]. One recent meta-analysis of RCT byMastenbroek et al [71]
concluded that PGS did not have a beneﬁcial effect on clinical
pregnancy rate, miscarriage rate, and live born rate among patient
with AMA and RIF. Therefore, it would seem there is no clear evi-
dence to support any beneﬁcial effect of PGS on IVF outcomes. The
general consensus at the moment is that RCTs have shown no
beneﬁt of PGS using cleavage stage biopsy, and this is probably
attributable to the high levels of mosaicism at the cleavage stage
and to the limitations of FISH. Furthermore, it would therefore
seem most useful for PGS RCTs to concentrate either on the PB or
trophectoderm biopsy approach and a full chromosome count [72e
74]. The ESHRE PGS task force is running a multicentere RCT to
determinewhether PGS truly does improve IVF outcome in patients
with AMA using PB biopsy and a-CGH.
Conclusion
PGD provides new hope of having unaffected children and helps
to avoid the possibility of terminating an affected spontaneous
pregnancy when genetic parents carry an affected gene or have
balanced chromosomal status. With the help of PCR-based molec-
ular techniques, the indication for PGD has been expanded. In the
past, FISH has been widely applied to detect chromosome abnor-
malities, and this has been applied to PGS in the situations of AMA,
a history of recurrent miscarriage, a history of RIF, or a partner with
very low sperm quality. Unfortunately, RCTs have not shown any
beneﬁt of PGS when used with cleavage stage biopsy, which is
probably attributable to the high levels of mosaicism at cleavage
stage and to the limitations of FISH.
Twomain types of array-based technology combined withWGA
are being developed for usewith PGD and have been shown to have
promising results. Further validation of these array platforms is
needed, and it remains to be decided which is the best embryo
stage to biopsy. If RCTs are able to show that array-based testing
using an optimal embryo biopsy stage increases delivery rates, this
will be a major step forward and help assisted reproductive tech-
nology patients around the world [74].
Finally, as Handyside [75] has noted, PGD should not be an
option available to only a few couples at risk of a serious genetic
condition who can afford the cost of the technique. With the
increasing emphasis in medicine on early diagnosis and prevention
of disease, together with the increasing availability of new molec-
ular genetic diagnostic tools, a national IVF-PGD program would
seem to be the next step in modern health care.
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